Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ANAB
HOLDAnaptysBio, Inc. · Healthcare · United States · $1.6B · Avg Vol: $40M/d
COMPANY DESCRIPTION
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic antibodies for inflammatory and immuno-oncology diseases. Its competitive moat stems from its proprietary SHM-P antibody discovery platform, which enables rapid generation of highly potent and selective therapeutic candidates. The company is a specialized player in biopharmaceutical innovation, aiming to address significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.3M | 17.2M | 91.3M | 234.6M | 183.6% | 232.4M | 94.3M | 153.2M | -19.2% |
| EPS | -4.57 | -6.08 | -5.12 | -0.46 | — | -0.89 | -0.23 | — | — |
| Shares | 28.5M | 26.6M | 30.5M | 28.0M | -1.7% | 29.6M | — | — | — |
| Debt | 19.4M | 17.8M | 16.0M | 14.1M | -10.1% | — | — | — | — |
| Equity | 262.1M | 88.1M | 70.9M | 37.2M | -47.8% | — | — | — | — |
| Op CF | -73.6M | -120.8M | -135.3M | 19.7M | — | 4.5M | — | — | — |
| Inv CF | -394.8M | 144.8M | 95.4M | 228.0M | — | — | — | — | — |
| Fin CF | 44.0M | -59.3M | 127.1M | -132.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANAB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ANAB | AnaptysBio, Inc.(you) | $1.6B | 47 | HOLD |
| URGN | UroGen Pharma Ltd. | $2.0B | 48 | HOLD |
| SRPT | Sarepta Therapeutics, Inc. | $1.7B | 36 | HOLD |
| SEPN | Septerna, Inc. | $1.5B | 36 | HOLD |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.5B | 42 | HOLD |
| FTRE | Fortrea Holdings Inc. | $1.8B | 58 | HOLD |
| LBRX | LB Pharmaceuticals Inc | $1.0B | 42 | HOLD |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 34 | SELL |
| ADMA | ADMA Biologics, Inc. | $1.9B | 35 | HOLD |
| NVAX | Novavax, Inc. | $1.2B | 37 | HOLD |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%